[
    [
        {
            "time": "",
            "original_text": "2018年最吸睛的跨国药企高管变动",
            "features": {
                "keywords": [
                    "跨国药企",
                    "高管变动"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2018年最吸睛的跨国药企高管变动",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "[强烈推荐评级]复星医药(600196)公司事件点评：CD20靶点利妥昔单抗类似药III期临床完成 上市在即",
            "features": {
                "keywords": [
                    "复星医药",
                    "CD20靶点",
                    "利妥昔单抗",
                    "III期临床",
                    "上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强烈推荐评级]复星医药(600196)公司事件点评：CD20靶点利妥昔单抗类似药III期临床完成 上市在即",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药生物行业事件点评：国家医疗保障局成立 结构化行情长期持续",
            "features": {
                "keywords": [
                    "国家医疗保障局",
                    "医药生物",
                    "结构化行情"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药生物行业事件点评：国家医疗保障局成立 结构化行情长期持续",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "盘后研报精选：关注这三只累积涨幅较大个股",
            "features": {
                "keywords": [
                    "盘后研报",
                    "累积涨幅",
                    "个股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "盘后研报精选：关注这三只累积涨幅较大个股",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业点评：金斯瑞CAR-T临床美国获批 中国细胞疗法又一里程碑",
            "features": {
                "keywords": [
                    "金斯瑞",
                    "CAR-T",
                    "临床",
                    "美国",
                    "细胞疗法"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业点评：金斯瑞CAR-T临床美国获批 中国细胞疗法又一里程碑",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【平安重点】行业专题报告*生物医药*PD-1/PD-L1元年，领先公司：抢先上市+联合用药*强于大市",
            "features": {
                "keywords": [
                    "生物医药",
                    "PD-1",
                    "PD-L1",
                    "抢先上市",
                    "联合用药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【平安重点】行业专题报告*生物医药*PD-1/PD-L1元年，领先公司：抢先上市+联合用药*强于大市",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "午评：恒指涨0.75%企稳30000点 “三桶油”集体走高",
            "features": {
                "keywords": [
                    "恒指",
                    "三桶油",
                    "涨"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "能源"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "午评：恒指涨0.75%企稳30000点 “三桶油”集体走高",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药股泡沫破了？",
            "features": {
                "keywords": [
                    "医药股",
                    "泡沫破了"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药股泡沫破了？",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "5月31日券商晨会研报汇编",
            "features": {
                "keywords": [
                    "券商晨会",
                    "研报汇编"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "5月31日券商晨会研报汇编",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医疗股大跌原因找到了，可以低吸这些龙头！",
            "features": {
                "keywords": [
                    "医疗股",
                    "大跌",
                    "低吸",
                    "龙头"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医疗股大跌原因找到了，可以低吸这些龙头！",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【山证医药】医药行业19年中期策略：科创助力产业升级，生物医药迎黄金发展期",
            "features": {
                "keywords": [
                    "山证医药",
                    "产业升级",
                    "生物医药",
                    "黄金发展期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【山证医药】医药行业19年中期策略：科创助力产业升级，生物医药迎黄金发展期",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "奇瑞混改疑云：与姚振华“争抢”奇瑞 郭广昌入局造车第一站？",
            "features": {
                "keywords": [
                    "奇瑞",
                    "混改",
                    "姚振华",
                    "郭广昌",
                    "造车"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "汽车"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "奇瑞混改疑云：与姚振华“争抢”奇瑞 郭广昌入局造车第一站？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]